Italia markets open in 5 hours 44 minutes

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
27,80-0,71 (-2,49%)
Alla chiusura: 04:00PM EST
27,80 0,00 (0,00%)
Dopo ore: 04:02PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente28,51
Aperto28,46
Denaro27,72 x 1200
Lettera30,42 x 800
Min-Max giorno27,60 - 29,12
Intervallo di 52 settimane19,86 - 41,46
Volume337.097
Media Volume583.654
Capitalizzazione4,346B
Beta (5 anni mensile)1,64
Rapporto PE (ttm)N/D
EPS (ttm)-1,71
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A40,40
  • GlobeNewswire

    Cerevel Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. Event: Guggenheim Healthcare Talks 4th Annual Immunology & Neurology DayDate: Tuesday, November 15, 2022Format: One-on-one meetings Event: Stifel 2022 Healthcare ConferenceDate: Wednesday, November 16, 2022Format:

  • GlobeNewswire

    Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

    Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclidine in Alzheimer’s disease psychosis; Phase 1 trial in healthy, elderly volunteers to be initiated by year-end Cash, cash equivalents and marketable securities of $1,030 million as of September 30, 2022, expected to support opera

  • GlobeNewswire

    Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022

    CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S. financial markets open. Management will host a conference call to discuss third quarter 2022 financial results and recent business updates on Tuesday, November 8, 2022, at 8:00 a.m. ET. To access the call